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Background
HIV prevalence in Ukraine is estimated at 1.6%, with
women comprising around half of the HIV-infected pop-
ulation, the vast majority of childbearing age. MTCT rates
declined to 7–10% in 2007 following implementation of
a national prevention of MTCT (PMTCT) programme in
2000, which to date has been based on single dose NVP
(sdNVP) and/or short-course zidovudine. Little informa-
tion is available on the natural and treated history of HIV
infection in children living in Eastern Europe.
Methods
Within the European Collaborative Study, HIV-infected
pregnant women and their infants were enrolled in 6 cit-
ies since 2000. Data on HIV-infected children followed
from birth to December 2008 were analyzed from this
ongoing study.
Results
There were a total of 162 infected children (47% female,
52% male), with average age at last follow-up of 19.1
months (IQR 9.1–44.0). A quarter had low birth weight,
19% (n = 31) were preterm and 25% delivered by Caesar-
ean Section; 37% (n = 60) of mothers had an injecting
drug use history. Most (n = 160) infants were bottlefed;
four were breastfed briefly. Most (147, 91%) children
were infected despite PMTCT prophylaxis (mostly single
dose NVP, 62%). Ninety-two children had ≥ 1 CD4
counts; based on nadir CD4 count to date, half (n = 49)
were classified in CDC immunological stage I, with 34%
(n = 31) and 13% (n = 12) in CDC stage II and III, respec-
tively. Forty-one percent (n = 66) of children had started
highly active antiretroviral treatment (HAART) by most
recent follow-up, at a median CD4 count of 1340 cells/
mm3; of those with viral load measurements, 15.5% (n =
13/84) on treatment had achieved an undetectable viral
load to date. Seventy-seven (48%) received PCP prophy-
laxis (mainly cotrimoxazole) and 8 children received TB
prophylaxis. Overall, 3% of children were ever anaemic,
with median haemoglobin of 11.5 gm/dl (range, 3.9–23.2
gm/dl). Twenty-two (14%) children had died by last fol-
low-up, with a median age at death of 14.5 months
(range, 1–47 months); nearly half (10, 45%) had devel-
oped AIDS before their death. Of the children who died,
only one had been started on HAART (and had received
cotrimoxazole). The most common causes of death were
pneumonia (n = 5) and sepsis (n = 5). Overall, 7% (n =
11) children developed AIDS during follow-up. From sur-
vival analysis, estimated AIDS-free survival rates were
94%, 90% and 87% for children at age six, twelve and
eighteen months, respectively. Survival analysis indicated
a significantly improved survival rate among children
born in 2004–2008 compared with those born earlier (P
= 0.0002). The mothers of nine infected children were
known to have died.
Conclusion
Less than half of our cohort of infected children had
received HAART and/or PCP prophylaxis. However, the
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improvements in AIDS-free survival in more recent years
reflect the scale-up of paediatric treatment in Ukraine.Page 2 of 2
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